EP0580750A1 - Multi-isotope imaging using energy-weighted acquisition for, e.g., myocardial perfusion studies - Google Patents

Multi-isotope imaging using energy-weighted acquisition for, e.g., myocardial perfusion studies

Info

Publication number
EP0580750A1
EP0580750A1 EP92910910A EP92910910A EP0580750A1 EP 0580750 A1 EP0580750 A1 EP 0580750A1 EP 92910910 A EP92910910 A EP 92910910A EP 92910910 A EP92910910 A EP 92910910A EP 0580750 A1 EP0580750 A1 EP 0580750A1
Authority
EP
European Patent Office
Prior art keywords
isotopes
isotope
information
weighting
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92910910A
Other languages
German (de)
French (fr)
Inventor
Raymond P. Devito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Medical Solutions USA Inc
Original Assignee
Siemens Gammasonics Inc
Siemens Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Gammasonics Inc, Siemens Medical Systems Inc filed Critical Siemens Gammasonics Inc
Publication of EP0580750A1 publication Critical patent/EP0580750A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01T—MEASUREMENT OF NUCLEAR OR X-RADIATION
    • G01T1/00—Measuring X-radiation, gamma radiation, corpuscular radiation, or cosmic radiation
    • G01T1/16—Measuring radiation intensity
    • G01T1/161—Applications in the field of nuclear medicine, e.g. in vivo counting
    • G01T1/164—Scintigraphy
    • G01T1/1641—Static instruments for imaging the distribution of radioactivity in one or two dimensions using one or several scintillating elements; Radio-isotope cameras
    • G01T1/1642—Static instruments for imaging the distribution of radioactivity in one or two dimensions using one or several scintillating elements; Radio-isotope cameras using a scintillation crystal and position sensing photodetector arrays, e.g. ANGER cameras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
    • A61B6/42—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment with arrangements for detecting radiation specially adapted for radiation diagnosis
    • A61B6/4208—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment with arrangements for detecting radiation specially adapted for radiation diagnosis characterised by using a particular type of detector
    • A61B6/4258—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment with arrangements for detecting radiation specially adapted for radiation diagnosis characterised by using a particular type of detector for detecting non x-ray radiation, e.g. gamma radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
    • A61B6/02—Devices for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computerised tomographs
    • A61B6/037—Emission tomography

Definitions

  • the invention relates to nuclear medicine, and more particularly relates to nuclear medicine studies in which more than one isotope is administered to the patient. In its most immediate sense, the invention relates to dual- isotope myocardial perfusion studies.
  • cardiac problems There are two major categories of cardiac problems. One category includes patients who have cardiac infarctions (dead myocardial tissue) . The other category includes patients who have arteriosclerosis (disease of the coronary arteries) . Clinically, it is necessary to distinguish between these two categories because they are managed differently. (When a cardiac patient is shown to have an infarcted myocardium, no surgical intervention is used and the patient is medicated and instructed to avoid heavy physical activity. When a cardiac patient is shown to have arteriosclerosis, surgical intervention can be used to correct the problem.)
  • Tl this is most commonly used, but Tc can also be used
  • the stress test can be administered physically, in which case the patient is placed on a treadmill.
  • the stress test can be administered pharmacologically by administering a dipyridamole drug sold under the I.V. PERSANTINE trademark by Du Pont Merck Pharmaceutical Co.
  • the Tl collects in the myocardium (heart muscle) and its initial distribution within the myocardium shows the regions where the myocardium is perfused with blood flow. Then, the patient's heart is imaged in a gamma camera to record this heart-under- stress blood perfusion. Afterward, the patient is permitted to rest so that the stress conditions entirely dissipate. As this happens, the Tl redistributes itself within the heart, and after a period of time (aided in some, but not all, instances by another injection of Tl) the distribution of Tl within the myocardium represents blood perfusion in the heart at rest. Then, the patient's heart is imaged a second time in a gamma camera to record this heart-at-rest blood perfusion.
  • a region of the myocardium shows Tl uptake when the heart is at rest, this indicates that this region contains living tissue. If the same region of the myocardium then lacks Tl uptake when the heart is stressed, this indicates the presence of arteriosclerosis which prevents blood from reaching region under stress conditions. On the other hand, if a region of the myocardium shows no Tl uptake either at rest or under stress, this indicates that the region contains an infarction which blood does not perfuse.
  • This conventional myocardial perfusion protocol takes a long time. Typically, the study lasts an entire day. This is because each session in the camera lasts about an hour and the interval between sessions is four hours. Camera throughput is low and study cost is consequently high.
  • Dr. Berman's research has developed a study protocol which would drastically shorten the duration of such myocardial perfusion studies.
  • the resting patient is first injected with a Tl agent.
  • the Tl will be taken up by the heart in accordance with heart-at-rest blood perfusion.
  • the patient is subjected to a stress test and injected, at peak stress, with the Tc CARDIOLITE agent.
  • This agent too is taken up within a few minutes.
  • the patient is placed in a gamma camera and a dual-isotope study of the patient is conducted.
  • Such a dual isotope study produces two images - a Tl image and a Tc image - of the patient's heart and the relationship between the images shows where heart muscle is affected by arteriosclerosis and where it is infarcted.
  • One object of this invention is to provide method and apparatus which could be used in multi-isotope studies, particularly dual-isotope studies, wherein crosstalk between the resulting images would be reduced.
  • Another object is to provide method and apparatus which could be used to improve the images produced by a dual-isotope myocardial perfusion study.
  • a further object is to provide method and apparatus by which existing gamma cameras with dual-isotope capability could be retrofitted so as to be usable in dual-isotope myocardial perfusion studies.
  • Still another object is to improve on method and apparatus of this general type.
  • the present invention compensates for crosstalk between isotope channels by using as many energy weighting functions as there are isotopes in the study and applying these weighting functions to information acquired.
  • each event is separately weighted using each function.
  • each frame is weighted.
  • the spectra are deconvolved.
  • each event, frame, spectrum etc. is utilized in a statistically appropriate manner. This reduces crosstalk, which results from statistically inappropriate treatment of information.
  • Fig. 1 shows how information is acquired and used in a conventional dual-isotope study
  • Fig. 2 shows how information is acquired and used in accordance with a first preferred embodiment of the invention
  • Fig. 3 shows how information is acquired and used in accordance with a second preferred embodiment of the invention
  • Fig. 4 shows how information is acquired and used in accordance with a third preferred embodiment of the invention.
  • Fig. 5 shows how information is acquired and used in accordance with a fourth preferred embodiment of the invention.
  • incoming scintillation events are tested for energies which lie in two pre-established energy windows.
  • the energy of each event is evaluated. If the energy of the event falls outside both windows, the event is completely discarded. If the energy of the event falls within, e.g., the Tl window, the event is counted as a Tl event and added to the set of events which will contribute to the formation of a Tl image. If the energy of the event falls within, e.g., the Tc window, the event is counted as a Tc event and added to the set of events which will contribute to the formation of a Tc image.
  • the energy response of a gamma camera to monoenergetic gamma rays is not monoenergetic.
  • events may be categorized in the wrong window and wrongly counted. If, for example, a dual isotope study is carried out with Tl-201 and Tc-99m, many of the Tc-99m events will have energies that fall outside the Tc-99m window and inside the Tl-201 window.
  • Tl-201 events are not always counted as such and some of such events are counted as Tc-99m events.
  • Such "crosstalk" causes the Tc image to be based on non-Tc events and causes the Tl image to be based on non-Tl events.
  • this is done in real time on an event-by-event basis.
  • each event contributes to each image, but the weight of the contribution is determined by weighting functions.
  • a first weighting function is for isotope X in the presence of isotope Y and a second weighting function is for isotope Y in the presence of isotope X.
  • post-processing is carried out, but this time on an energy-dependent frame-by-frame basis.
  • each frame is constructed from data which meets energy-based criteria and each frame, after appropriate weighting, contributes to each image.
  • the weighting is actually a convolution of the respective frame data.
  • data is processed not on an event-by-event or a frame-by-frame basis, but rather on a region-by-region basis (it being understood that a "region" may be as small as a single pixel) .
  • region the energy spectrum of events which occur in the region is accumulated and this spectrum is analyzed to deduce the amounts of the isotopes which are present.
  • This analysis can be carried out by fitting the acquired energy spectrum with the known energy responses of, e.g., the two isotopes (X and Y) used. In other words, the energy responses for isotopes X and Y are known.
  • the system determines what combination of isotopes X and Y would produce the acquired energy spectrum for each region in the image. This calculation will produce a quantity of isotope X and a quantity of isotope Y at that region.
  • the result is two separated images, one for isotope X and the other for isotope Y.
  • the image produced in accordance with each of the preferred embodiments can be either planar or tomographic. Obviously, production of a tomographic image requires the use of a rotating element so as to acquire the requisite number of views.
  • a weighting function was derived for use with Tc-99m and Tl-201 and was constructed to take account of resolution, noise and energy response uniformity of the camera system.
  • Selection of an appropriate weighting function is then carried out by defining a generalized chi-square measure of quality (Q, see page 345 of the referenced article) for each of the isotopes and optimizing it using a gradient search method as is described at page 346.
  • the optimization process is carried out under two constraints: the normalization of the weighted point spread function for the principal isotope (X) is required to match that of the point spread function using a standard fixed energy window, and the values for the different terms of the weighting function are maintained within the limits required by the imaging hardware.
  • the ideal weighting function is required to adhere to the constraint that where a weighting function is used, e.g.
  • the weighting function for isotope X in the presence of isotope Y produce a good point spread function for X and a zero or non-peaked point spread function for isotope Y, and likewise for the weighting function for isotope Y in the presence of X.

Abstract

On effectue une étude multi-isotopes en utilisant une multiplicité d'agents de visualisation dont les images sont simultanément visualisées. Les données obtenues sont pondérées à l'aide d'autant de fonctions de pondération par énergie que d'isotopes utilisés. La pondération réduit "l'interférence" entre chacune des images à isotope unique produites du fait de cette étude. Ceci permet d'obtenir de meilleurs résultats, par exemple, dans des études de perfusion myocardique à double isotope (Tc-99m et Tl-201).A multi-isotope study is carried out using a multiplicity of visualization agents whose images are simultaneously visualized. The data obtained are weighted using as many energy weighting functions as there are isotopes used. The weighting reduces "interference" between each of the single isotope images produced as a result of this study. This allows better results, for example, in double isotope myocardial perfusion studies (Tc-99m and Tl-201).

Description

MULTI-ISOTOPE IMAGING USING ENERGY-WEIGHTED ACQUISTION FOR, E.G., MYOCARDIAL PERFUSION STUDIES
BACKGROUND OF THE INVENTION The invention relates to nuclear medicine, and more particularly relates to nuclear medicine studies in which more than one isotope is administered to the patient. In its most immediate sense, the invention relates to dual- isotope myocardial perfusion studies.
It has long been known to administer e.g. two radioisotopes to a patient and to form two images of the patient, one relating to one isotope and the other relating to the other isotope. U.S. Patent No. 3,904,530 teaches apparatus which is designed to be used in such a study. Presently, the only significant clinical application of a dual-isotope study is a parathyroid study. Such a study is designed to detect the existence of an adenoma (which takes up Tl) on the thyroid (which takes up both Tc and Tl) . In this study, subtraction of the Tc image from the Tl image will reveal the adenoma.
Recently, Daniel S. Berman, M.D. at the Cedars-Sinai Medical Center (Los Angeles, CA) has proposed to improve existing myocardial perfusion studies by using a dual- isotope technique and utilizing a recently developed Tc- 99m sestamibi pharmaceutical marketed by Du Pont Merck Pharmaceutical Co. (Wilmington, DE) under the CARDIOLITE trademark. The present invention has particular utility in such studies and to understand this utility it is necessary to understand the purposes and protocols used in myocardial perfusion studies. This will now be explained.
There are two major categories of cardiac problems. One category includes patients who have cardiac infarctions (dead myocardial tissue) . The other category includes patients who have arteriosclerosis (disease of the coronary arteries) . Clinically, it is necessary to distinguish between these two categories because they are managed differently. (When a cardiac patient is shown to have an infarcted myocardium, no surgical intervention is used and the patient is medicated and instructed to avoid heavy physical activity. When a cardiac patient is shown to have arteriosclerosis, surgical intervention can be used to correct the problem.)
A myocardial perfusion nuclear medicine study is presently used to distinguish between these two categories of problems. In such a study, Tl (this is most commonly used, but Tc can also be used) is administered to a patient while the patient has reached the point of maximum effort in a stress test. (The stress test can be administered physically, in which case the patient is placed on a treadmill. Alternatively, for bedridden patients, the stress test can be administered pharmacologically by administering a dipyridamole drug sold under the I.V. PERSANTINE trademark by Du Pont Merck Pharmaceutical Co. This also increases blood flow to the heart muscle.) The Tl collects in the myocardium (heart muscle) and its initial distribution within the myocardium shows the regions where the myocardium is perfused with blood flow. Then, the patient's heart is imaged in a gamma camera to record this heart-under- stress blood perfusion. Afterward, the patient is permitted to rest so that the stress conditions entirely dissipate. As this happens, the Tl redistributes itself within the heart, and after a period of time (aided in some, but not all, instances by another injection of Tl) the distribution of Tl within the myocardium represents blood perfusion in the heart at rest. Then, the patient's heart is imaged a second time in a gamma camera to record this heart-at-rest blood perfusion.
If a region of the myocardium shows Tl uptake when the heart is at rest, this indicates that this region contains living tissue. If the same region of the myocardium then lacks Tl uptake when the heart is stressed, this indicates the presence of arteriosclerosis which prevents blood from reaching region under stress conditions. On the other hand, if a region of the myocardium shows no Tl uptake either at rest or under stress, this indicates that the region contains an infarction which blood does not perfuse. This conventional myocardial perfusion protocol takes a long time. Typically, the study lasts an entire day. This is because each session in the camera lasts about an hour and the interval between sessions is four hours. Camera throughput is low and study cost is consequently high.
Dr. Berman's research has developed a study protocol which would drastically shorten the duration of such myocardial perfusion studies. According to this new study protocol, the resting patient is first injected with a Tl agent. In a few minutes, the Tl will be taken up by the heart in accordance with heart-at-rest blood perfusion. Thereafter, the patient is subjected to a stress test and injected, at peak stress, with the Tc CARDIOLITE agent. This agent too is taken up within a few minutes. Then, the patient is placed in a gamma camera and a dual-isotope study of the patient is conducted. Such a dual isotope study produces two images - a Tl image and a Tc image - of the patient's heart and the relationship between the images shows where heart muscle is affected by arteriosclerosis and where it is infarcted.
This new study protocol produces dramatic improvement in camera throughput, because the prolonged wait between injections is eliminated and only one camera session is needed instead of two. This is a major development because myocardial perfusion studies are the second most common application for nuclear medicine.
Conventional gamma cameras with dual-isotope capability are not able to make optimum use of this new study protocol. This is because there is a degree of crosstalk between the two acquisition channels, i.e. events from the Tc channel will be counted in the Tl channel and vice versa. In the case of parathyroid studies, this is not particularly disadvantageous, but in cardiac applications this would significantly degrade the diagnostic utility of the images produced. It would therefore be advantageous to provide gamma cameras with improved crosstalk characteristics so as to better benefit from this new study protocol.
One object of this invention is to provide method and apparatus which could be used in multi-isotope studies, particularly dual-isotope studies, wherein crosstalk between the resulting images would be reduced.
Another object is to provide method and apparatus which could be used to improve the images produced by a dual-isotope myocardial perfusion study. A further object is to provide method and apparatus by which existing gamma cameras with dual-isotope capability could be retrofitted so as to be usable in dual-isotope myocardial perfusion studies.
Still another object is to improve on method and apparatus of this general type.
The present invention compensates for crosstalk between isotope channels by using as many energy weighting functions as there are isotopes in the study and applying these weighting functions to information acquired. Where the information is acquired on an event- by-event basis, each event is separately weighted using each function. Where the information is acquired on a frame-by-frame basis, each frame is weighted. Where the information is acquired on a spectral basis, the spectra are deconvolved.
By weighting all the information acquired, each event, frame, spectrum etc. is utilized in a statistically appropriate manner. This reduces crosstalk, which results from statistically inappropriate treatment of information.
BRIEF DESCRIPTION OF THE DRAWINGS The invention will be better understood with reference to the following illustrative and non-limiting drawings, in which:
Fig. 1 shows how information is acquired and used in a conventional dual-isotope study; Fig. 2 shows how information is acquired and used in accordance with a first preferred embodiment of the invention;
Fig. 3 shows how information is acquired and used in accordance with a second preferred embodiment of the invention;
Fig. 4 shows how information is acquired and used in accordance with a third preferred embodiment of the invention; and
Fig. 5 shows how information is acquired and used in accordance with a fourth preferred embodiment of the invention.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS In a conventional dual-isotope study, incoming scintillation events are tested for energies which lie in two pre-established energy windows. Thus, as shown in Fig. 1, the energy of each event is evaluated. If the energy of the event falls outside both windows, the event is completely discarded. If the energy of the event falls within, e.g., the Tl window, the event is counted as a Tl event and added to the set of events which will contribute to the formation of a Tl image. If the energy of the event falls within, e.g., the Tc window, the event is counted as a Tc event and added to the set of events which will contribute to the formation of a Tc image. However, as is known to persons skilled in the art, the energy response of a gamma camera to monoenergetic gamma rays is not monoenergetic. As a result of many factors, events may be categorized in the wrong window and wrongly counted. If, for example, a dual isotope study is carried out with Tl-201 and Tc-99m, many of the Tc-99m events will have energies that fall outside the Tc-99m window and inside the Tl-201 window. Likewise, Tl-201 events are not always counted as such and some of such events are counted as Tc-99m events. Such "crosstalk" causes the Tc image to be based on non-Tc events and causes the Tl image to be based on non-Tl events.
While this is not a major problem in the case of parathyroid studies, it is such a problem in the case of dual-isotope myocardial perfusion studies. This is because in such a perfusion study, the two isotopes are much more intermingled and the regions of interest are relatively small. For such a study to have sufficient clinical utility, the referenced "crosstalk" must be removed.
In the first preferred embodiment, this is done in real time on an event-by-event basis. Where the study is of the dual-isotope type, each event contributes to each image, but the weight of the contribution is determined by weighting functions. Thus, where X and Y are the isotopes used, a first weighting function is for isotope X in the presence of isotope Y and a second weighting function is for isotope Y in the presence of isotope X. (The construction of these weighting functions will be discussed below. However, it is appropriate to note that in, e.g. a three-isotope study, there would be isotopes X, Y and Z, the first weighting function would be for isotope X in the presence of isotopes Y and Z, the second weighting function would be for isotope Y in the presence of isotopes X and Z, and the third weighting function would be for Z in the presence of X and Y.) In the second preferred embodiment, the same thing is done but on a post-processing basis. Here, each event is recorded and after the study has been completed, all the events are processed.
In the third preferred embodiment, post-processing is carried out, but this time on an energy-dependent frame-by-frame basis. Here, each frame is constructed from data which meets energy-based criteria and each frame, after appropriate weighting, contributes to each image. In this embodiment, the weighting is actually a convolution of the respective frame data.
In the fourth preferred embodiment, which likewise is carried out in a post-processing mode, data is processed not on an event-by-event or a frame-by-frame basis, but rather on a region-by-region basis (it being understood that a "region" may be as small as a single pixel) . For each region, the energy spectrum of events which occur in the region is accumulated and this spectrum is analyzed to deduce the amounts of the isotopes which are present. This analysis can be carried out by fitting the acquired energy spectrum with the known energy responses of, e.g., the two isotopes (X and Y) used. In other words, the energy responses for isotopes X and Y are known. For each region, the system determines what combination of isotopes X and Y would produce the acquired energy spectrum for each region in the image. This calculation will produce a quantity of isotope X and a quantity of isotope Y at that region.
When the calculation is repeated for all regions of the image, the result is two separated images, one for isotope X and the other for isotope Y.
The image produced in accordance with each of the preferred embodiments can be either planar or tomographic. Obviously, production of a tomographic image requires the use of a rotating element so as to acquire the requisite number of views.
In the present instance, a weighting function was derived for use with Tc-99m and Tl-201 and was constructed to take account of resolution, noise and energy response uniformity of the camera system.
First, the Energy Dependent Point Source Response function (EPSF) is measured for each isotope. This procedure is described at page 344 of an article entitled Determination of Weighting Functions for Energy-Weighted Acquisition which was published in February, 1991 in The Journal of Nuclear Medicine, Vol. 32, No. 2, pp. 343 - 349.
Selection of an appropriate weighting function is then carried out by defining a generalized chi-square measure of quality (Q, see page 345 of the referenced article) for each of the isotopes and optimizing it using a gradient search method as is described at page 346. As is stated there, the optimization process is carried out under two constraints: the normalization of the weighted point spread function for the principal isotope (X) is required to match that of the point spread function using a standard fixed energy window, and the values for the different terms of the weighting function are maintained within the limits required by the imaging hardware. The ideal weighting function is required to adhere to the constraint that where a weighting function is used, e.g. for two isotopes X and Y, the weighting function for isotope X in the presence of isotope Y produce a good point spread function for X and a zero or non-peaked point spread function for isotope Y, and likewise for the weighting function for isotope Y in the presence of X.
Although a preferred embodiment has been described above, the scope of the invention is limited only by the following claims:

Claims

Claims :
1. A method of conducting a multi-isotope study using a gamma camera and a plurality of isotopes, comprising the step of weighting the information acquired by the gamma camera with as many weighting functions as there are isotopes.
2. The method of claim 1, further comprising the step of producing as many planar images as there are isotopes.
3. The method of claim 1, further comprising the step of producing as many tomographic images as there are isotopes.
4. A method of conducting a multi-isotope study using a gamma camera and a plurality of isotopes, said gamma camera producing information in an event-by-event format, the method comprising the step of weighting the information in real time using as many energy-based weighting functions as there are isotopes and producing as many images as there are isotopes.
5. A method of conducting a multi-isotope study using a gamma camera and a plurality of isotopes, said gamma camera producing information in an event-by-event format, the method comprising the step of weighting the information using as many energy-based weighting functions as there are isotopes and producing as many images as there are isotopes, said weighting step being carried out in a post-processing mode after all the information has been accumulated.
6. A method of conducting a multi-isotope study using a gamma camera and a plμrality of isotopes, said gamma camera producing information in a frame-by-frame format, the method comprising the step of weighting the information using as many energy-based weighting convolution functions as there are isotopes and producing as many images as there are isotopes, said weighting step being carried out in a post-processing mode after all the information has been accumulated.
7. A method of conducting a multi-isotope study using a gamma camera and a plurality of isotopes, said gamma camera producing information in a region-by-region format, the method comprising the step of spectrally deconvolving the information using as many energy spectrum-based deconvolution functions as there are isotopes and producing as many images as there are isotopes, said weighting step being carried out in a post-processing mode after all the information has been accumulated.
EP92910910A 1991-04-16 1992-02-11 Multi-isotope imaging using energy-weighted acquisition for, e.g., myocardial perfusion studies Withdrawn EP0580750A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/685,940 US5249124A (en) 1991-04-16 1991-04-16 Multi-isotope imaging using energy-weighted acquisition for, e.g., myocardial perfusion studies
US685940 1991-04-16

Publications (1)

Publication Number Publication Date
EP0580750A1 true EP0580750A1 (en) 1994-02-02

Family

ID=24754289

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92910910A Withdrawn EP0580750A1 (en) 1991-04-16 1992-02-11 Multi-isotope imaging using energy-weighted acquisition for, e.g., myocardial perfusion studies

Country Status (5)

Country Link
US (1) US5249124A (en)
EP (1) EP0580750A1 (en)
JP (1) JPH06506773A (en)
IL (1) IL100785A0 (en)
WO (1) WO1992018881A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610402A (en) * 1994-03-30 1997-03-11 Kabushiki Kaisha Toshiba Scintillation camera
US6008493A (en) * 1997-05-30 1999-12-28 Adac Laboratories Method and apparatus for performing correction of emission contamination and deadtime loss in a medical imaging system
EP0969293B1 (en) * 1998-06-30 2003-02-26 Marconi Medical Systems, Inc. Nuclear camera system using radio-isotopes
US6445945B1 (en) 2000-06-26 2002-09-03 André Arsenault Non-invasive detection of endothelial dysfunction by blood flow measurement in opposed limbs using tracer injection
US8909325B2 (en) 2000-08-21 2014-12-09 Biosensors International Group, Ltd. Radioactive emission detector equipped with a position tracking system and utilization thereof with medical systems and in medical procedures
US8489176B1 (en) 2000-08-21 2013-07-16 Spectrum Dynamics Llc Radioactive emission detector equipped with a position tracking system and utilization thereof with medical systems and in medical procedures
US8036731B2 (en) 2001-01-22 2011-10-11 Spectrum Dynamics Llc Ingestible pill for diagnosing a gastrointestinal tract
US7826889B2 (en) 2000-08-21 2010-11-02 Spectrum Dynamics Llc Radioactive emission detector equipped with a position tracking system and utilization thereof with medical systems and in medical procedures
US8565860B2 (en) 2000-08-21 2013-10-22 Biosensors International Group, Ltd. Radioactive emission detector equipped with a position tracking system
WO2005119025A2 (en) 2004-06-01 2005-12-15 Spectrum Dynamics Llc Radioactive-emission-measurement optimization to specific body structures
CN1310617C (en) 2001-01-22 2007-04-18 V-目标技术有限公司 Ingestible pill
US20040116807A1 (en) * 2002-10-17 2004-06-17 Roni Amrami Blood vessels wall imaging catheter
AU2003276658A1 (en) * 2002-11-04 2004-06-07 V-Target Technologies Ltd. Apparatus and methods for imaging and attenuation correction
US20070037208A1 (en) * 2003-05-29 2007-02-15 Foote Robert S Method for detecting cardiac ischemia via changes in b-natriuretic peptide levels
US9470801B2 (en) 2004-01-13 2016-10-18 Spectrum Dynamics Llc Gating with anatomically varying durations
WO2005118659A2 (en) 2004-06-01 2005-12-15 Spectrum Dynamics Llc Methods of view selection for radioactive emission measurements
US8586932B2 (en) 2004-11-09 2013-11-19 Spectrum Dynamics Llc System and method for radioactive emission measurement
WO2005067383A2 (en) 2004-01-13 2005-07-28 Spectrum Dynamics Llc Multi-dimensional image reconstruction
US8571881B2 (en) 2004-11-09 2013-10-29 Spectrum Dynamics, Llc Radiopharmaceutical dispensing, administration, and imaging
US7968851B2 (en) 2004-01-13 2011-06-28 Spectrum Dynamics Llc Dynamic spect camera
WO2007010537A2 (en) 2005-07-19 2007-01-25 Spectrum Dynamics Llc Reconstruction stabilizer and active vision
WO2008010227A2 (en) 2006-07-19 2008-01-24 Spectrum Dynamics Llc Imaging protocols
EP1827505A4 (en) 2004-11-09 2017-07-12 Biosensors International Group, Ltd. Radioimaging
US8615405B2 (en) 2004-11-09 2013-12-24 Biosensors International Group, Ltd. Imaging system customization using data from radiopharmaceutical-associated data carrier
US8423125B2 (en) 2004-11-09 2013-04-16 Spectrum Dynamics Llc Radioimaging
US9943274B2 (en) 2004-11-09 2018-04-17 Spectrum Dynamics Medical Limited Radioimaging using low dose isotope
US9316743B2 (en) 2004-11-09 2016-04-19 Biosensors International Group, Ltd. System and method for radioactive emission measurement
WO2008059489A2 (en) 2006-11-13 2008-05-22 Spectrum Dynamics Llc Radioimaging applications of and novel formulations of teboroxime
EP1844351A4 (en) 2005-01-13 2017-07-05 Biosensors International Group, Ltd. Multi-dimensional image reconstruction and analysis for expert-system diagnosis
US8644910B2 (en) 2005-07-19 2014-02-04 Biosensors International Group, Ltd. Imaging protocols
US8837793B2 (en) 2005-07-19 2014-09-16 Biosensors International Group, Ltd. Reconstruction stabilizer and active vision
EP1952180B1 (en) 2005-11-09 2017-01-04 Biosensors International Group, Ltd. Dynamic spect camera
US8204500B2 (en) 2005-12-28 2012-06-19 Starhome Gmbh Optimal voicemail deposit for roaming cellular telephony
US8894974B2 (en) 2006-05-11 2014-11-25 Spectrum Dynamics Llc Radiopharmaceuticals for diagnosis and therapy
US7601966B2 (en) 2006-06-28 2009-10-13 Spectrum Dynamics Llc Imaging techniques for reducing blind spots
WO2008075362A2 (en) 2006-12-20 2008-06-26 Spectrum Dynamics Llc A method, a system, and an apparatus for using and processing multidimensional data
US8521253B2 (en) 2007-10-29 2013-08-27 Spectrum Dynamics Llc Prostate imaging
US8557222B2 (en) 2008-04-04 2013-10-15 Avid Radiopharmaceuticals, Inc. Radiopharmaceutical imaging of neurodegenerative diseases
US8338788B2 (en) 2009-07-29 2012-12-25 Spectrum Dynamics Llc Method and system of optimized volumetric imaging
US8455834B2 (en) * 2009-12-02 2013-06-04 General Electric Company Systems and methods for patient positioning for nuclear medicine imaging

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950648A (en) * 1972-09-11 1976-04-13 Picker Corporation Scintillation camera
US4575810A (en) * 1983-03-11 1986-03-11 Siemens Gammasonics, Inc. Method and circuit for processing pulses by applying the technique of weighted acquisition
US4873632A (en) * 1984-04-27 1989-10-10 The Curators Of The University Of Missouri Apparatus and methods for scatter reduction in radiation imaging

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9218881A1 *

Also Published As

Publication number Publication date
WO1992018881A1 (en) 1992-10-29
IL100785A0 (en) 1992-09-06
US5249124A (en) 1993-09-28
JPH06506773A (en) 1994-07-28

Similar Documents

Publication Publication Date Title
US5249124A (en) Multi-isotope imaging using energy-weighted acquisition for, e.g., myocardial perfusion studies
Vaquero et al. Positron emission tomography: current challenges and opportunities for technological advances in clinical and preclinical imaging systems
US7872235B2 (en) Multi-dimensional image reconstruction and analysis for expert-system diagnosis
Jensen et al. Improvement in ventricular function during exercise studied with radionuclide ventriculography after cardiac rehabilitation
Chan et al. Use of the metabolic tracer carbon-11-acetate for evaluation of regional myocardial perfusion
Løkkegaard et al. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand
Ritchie et al. Radionuclide angiography: noninvasive assessment of hemodynamic changes after administration of nitroglycerin
Muntinga et al. Normal values and reproducibility of left ventricular filling parameters by radionuclide angiography
Borges-Neto et al. Combined exercise radionuclide angiocardiography and single photon emission computed tomography perfusion studies for assessment of coronary artery disease
JP2021533145A (en) Diagnosis of dopaminergic disorders and movement disorders
Alhassen et al. Myocardial blood flow measurement with a conventional dual-head SPECT/CT with spatiotemporal iterative reconstructions-a clinical feasibility study
Won et al. Recent trends in nuclear cardiology practice
Budinger et al. Three dimensional imaging of the myocardium with radionuclides
Wackers The maze of myocardial perfusion imaging protocols in 1994
Wu et al. Thallium-201 is comparable to technetium-99m-sestamibi for estimating cardiac function in patients with abnormal myocardial perfusion imaging
Hachamovitch Clinical application of rest thallium-201/stress technetium-99m sestamibi dual isotope myocardial perfusion single-photon emission computed tomography
Weldon Assessment of Inflammatory Bowel Disease Activity Using 99mTc-HMPAO single Photon Emission Computerized Tomography Imaging
Elgebaly et al. Evaluation of varying physical acquisition parameters in gamma camera gated cardiac SPECT
Taplin Studying organ circulation, function and structure with radioisotopes
Zafrir et al. Effect of dipyridamole on myocardial perfusion and function using technetium-99m MIBI
Rozanski Laboratory techniques for assessing the presence and magnitude of mental stress-induced myocardial ischemia in patients with coronary artery disease
Lagopati Nuclear Medicine Imaging Essentials
RU2032188C1 (en) Aortic ventricle deficiency determination method
Germano et al. Physics and technical aspects of gated myocardial perfusion SPECT
Shirazu et al. A Ten Years of the SPECT System Operation at the Korle-Bu Teaching Hospital

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930813

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB

17Q First examination report despatched

Effective date: 19940819

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SIEMENS MEDICAL SYSTEMS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960327